3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Brain Neoplasms
1
Interventions
Temozolomide
19
Magnetic Resonance Spectroscopy
16
Radiosurgery
12
Bevacizumab
12
Radiotherapy
10
Radiation
8
pembrolizumab
6
Specimen Handling
6
Methotrexate
6
Surgical Procedures, Operative
5
Topotecan
4
TIC10 compound
4
Isotretinoin
4
Carmustine
4
Carboplatin
4
abemaciclib
3
Trastuzumab
3
Thiotepa
3
Standard of Care
3
Nivolumab
3
Magnetic Resonance Imaging
3
Lomustine
3
Irinotecan
3
Erlotinib Hydrochloride
3
Drug Therapy
3
Dexamethasone
3
vandetanib
2
thymoglobulin
2
temsirolimus
2
pazopanib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
patritumab deruxtecan
×
CNS
×
Clear all
NCT05620914
2025-06-15
PARAMETer
Duke University
Phase 2
Withdrawn